Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42345 (
mTOR
)
26,049
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mitogens activate protein translation through phosphorylation of p7S6 kinase (p70(S6K)) and eIF4E binding protein 1 (4E-BP1) mediated by the
mammalian target of rapamycin
(
mTOR
) or phosphoinositide 3-kinase (PI3K). A recent report (Science 294, 1942, 2001) has implicated phospholipase D (PLD) in
mTOR
signaling. We studied the role of PLD in the phosphorylation of p70(S6K) and 4E-BP1 induced by lysophosphatidic acid (LPA) and platelet-derived growth factor (PDGF) using fibroblasts deficient in PLD activity and also 1-butanol, which inhibits phosphatidic acid production by PLD. The reduction in PLD activity in both situations impaired the effect of LPA on
mTOR
signaling but did not inhibit the effect of PDGF. PDGF induced marked phosphorylation of Akt (a PI3K target) but this was not affected by PLD deficiency. LPA caused much less phosphorylation of Akt and this was dependent on PLD activity. Toxin B, which inactivates Rho GTPases, markedly impaired
PLD1
activation and phosphorylation of Akt, p70(S6K), and 4E-BP1 induced by LPA but had a minimal or no effect on the actions of PDGF. These results support the hypothesis that LPA activates protein translation through the action of
PLD1
-generated PA on
mTOR
and the PI3K/Akt pathway whereas PDGF acts through P13K/Akt independent of
PLD1
.
...
PMID:Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid. 1476 25
Phospholipase D (PLD) has been reported to generate survival signals that prevent apoptosis induced by serum withdrawal. We have now found that elevated expression of PLD also suppresses DNA damage-induced apoptosis. Since DNA damage-induced apoptosis is often mediated by p53, we examined the effect of elevated PLD expression on the regulation of p53 stabilization. We report here that PLD suppresses DNA damage-induced increases in p53 stabilization in cells where PLD has been shown to provide a survival signal. Elevated expression of PLD also led to increased expression of the p53 E3 ubiquitin ligase MDM2 and increased turnover of p53.
PLD1
-stimulated increases in MDM2 expression and suppression of p53 activation were blocked by inhibition of
mTOR
and the mitogen-activated protein kinase pathway. Although PLD did not activate the phosphatidylinositol 3-kinase (PI3K)/Akt survival pathway activate the basal levels of PI3K activity were partially required for
PLD1
-induced increases in MDM2. These data provide evidence that survival signals generated by PLD involve suppression of the p53 response pathway.
...
PMID:Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. 1519 26
Signaling by the
mammalian target of rapamycin
(
mTOR
) has been reported to be necessary for mechanical load-induced growth of skeletal muscle. The mechanisms involved in the mechanical activation of
mTOR
signaling are not known, but several studies indicate that a unique [phosphotidylinositol-3-kinase (PI3K)- and nutrient-independent] mechanism is involved. In this study, we have demonstrated that a regulatory pathway for
mTOR
signaling that involves phospholipase D (PLD) and the lipid second messenger phosphatidic acid (PA) plays a critical role in the mechanical activation of
mTOR
signaling. First, an elevation in PA concentration was sufficient for the activation of
mTOR
signaling. Second, the isozymes of PLD (
PLD1
and PLD2) are localized to the z-band in skeletal muscle (a critical site of mechanical force transmission). Third, mechanical stimulation of skeletal muscle with intermittent passive stretch ex vivo induced PLD activation, PA accumulation, and
mTOR
signaling. Finally, pharmacological inhibition of PLD blocked the mechanically induced increase in PA and the activation of
mTOR
signaling. Combined, these results indicate that mechanical stimuli activate
mTOR
signaling through a PLD-dependent increase in PA. Furthermore, we showed that
mTOR
signaling was partially resistant to rapamycin in muscles subjected to mechanical stimulation. Because rapamycin and PA compete for binding to the FRB domain on
mTOR
, these results suggest that mechanical stimuli activate
mTOR
signaling through an enhanced binding of PA to the FRB domain on
mTOR
.
...
PMID:The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. 1653 99
In the current study, the involvement of phospholipase D (PLD) in the regulation of collagen type I production was examined using human dermal fibroblasts. Procollagen I production in the cells overexpressing
PLD1
, but not PLD2, was found to be increased compared with those in the vector control cells. To investigate the role of
PLD1
, we examined the effect of knockdown of endogenous
PLD1
by small interference RNA (siRNA) on collagen production. The reduction of expression levels of
PLD1
by siRNA transfection was accompanied by diminution of procollagen biosynthesis and also ribosomal S6 kinase 1 (S6K1) phosphorylation. The activity of
mammalian target of rapamycin
(
mTOR
) is essential for phosphorylation of S6K1 and the treatment of dermal fibroblasts with rapamycin, a potent inhibitor of
mTOR
abolished procollagen I production. These results suggest that
PLD1
plays a crucial role in collagen type I production through
mTOR
signaling in human dermal fibroblast.
...
PMID:Involvement of phospholipase D1 in collagen type I production of human dermal fibroblasts. 1691 39
A
mammalian target of rapamycin
(
mTOR
) pathway is essential for the differentiation of cultured skeletal myoblasts in response to growth factor withdrawal. Previously, phospholipase D (PLD) has been found to play a role in cell growth regulation and mitogenic activation of
mTOR
signaling. However, a role for PLD in the autocrine regulation of myoblast differentiation is not known. Here we show that upon induction of differentiation in mouse C2C12 satellite cells, the expression of both
PLD1
and PLD2 is upregulated. C2C12 differentiation is markedly inhibited by 1-butanol, an inhibitor of the PLD-catalyzed transphosphatidylation reaction, and also by the knockdown of
PLD1
, but not PLD2. Further investigation has revealed that
PLD1
is unlikely to regulate myogenesis through modulation of the actin cytoskeleton as previously suggested. Instead,
PLD1
positively regulates
mTOR
signaling leading to the production of IGF2, an autocrine factor instrumental for the initiation of satellite cell differentiation. Furthermore, exogenous IGF2 fully rescues the differentiation defect resulting from
PLD1
knockdown. Hence,
PLD1
is critically involved in skeletal myogenesis by regulating the
mTOR
-IGF2 pathway.
...
PMID:PLD regulates myoblast differentiation through the mTOR-IGF2 pathway. 1819 86
The
mammalian target of rapamycin
(
mTOR
) assembles a signaling network essential for the regulation of cell growth, which has emerged as a major target of anticancer therapies. The tuberous sclerosis complex 1 and 2 (TSC1/2) proteins and their target, the small GTPase Rheb, constitute a key regulatory pathway upstream of
mTOR
. Phospholipase D (PLD) and its product phosphatidic acid are also upstream regulators of the mitogenic
mTOR
signaling. However, how the TSC/Rheb and PLD pathways interact or integrate in the rapamycin-sensitive signaling network has not been examined before. Here, we find that
PLD1
, but not PLD2, is required for Rheb activation of the
mTOR
pathway, as demonstrated by the effects of RNAi. The overexpression of Rheb activates
PLD1
in cells in the absence of mitogenic stimulation, and the knockdown of Rheb impairs serum stimulation of PLD activation. Furthermore, the overexpression of TSC2 suppresses
PLD1
activation, whereas the knockdown or deletion of TSC2 leads to elevated basal activity of PLD. Consistent with a TSC-Rheb-PLD signaling cascade, AMPK and PI3K, both established regulators of TSC2, appear to lie upstream of PLD as revealed by the effects of pharmacological inhibitors, and serum activation of PLD is also dependent on amino acid sufficiency. Finally, Rheb binds and activates
PLD1
in vitro in a GTP-dependent manner, strongly suggesting that
PLD1
is a bona fide effector for Rheb. Hence, our findings reveal an unexpected interaction between two cascades in the
mTOR
signaling pathways and open up additional possibilities for targeting this important growth-regulating network for the development of anticancer drugs.
...
PMID:Phospholipase D1 is an effector of Rheb in the mTOR pathway. 1855 Aug 14
We have previously reported the participation of mitogen-activated protein, Rho, and phosphoinositide-3 (PI3) kinases in separate pathways in serotonin (5-HT)-induced proliferation of pulmonary artery smooth muscle cells (SMCs). In this study, we investigated the possible participation of phospholipase D (PLD) and phosphatidic acid (PA) in this growth process. 5-HT stimulated a time-dependent increase in [(3)H]phosphatidylbutanol and PA generation. Exposure of SMCs to 1-butanol or overexpression of an inactive mutant of human PLD1R898R blocked 5-HT-induced proliferation. Furthermore, 1-butanol inhibited 5-HT activation of S6K1 and S6 protein, downstream effectors of
mammalian target of rapamycin
(
mTOR
), by 80 and 72%, respectively, and partially blocked activation of extracellular signal-regulated kinase (ERK) by 30% but had no effect on other associated signaling pathways. Exogenous PA caused cellular proliferation and revitalized cyclin D1 expression by 5-HT of the 1-butanol-treated cells. PA also reproduced activations by 5-HT of
mTOR
, S6K1, and ERK. Transfection with inactive human
PLD1
reduced 5-HT-induced activation of S6K1 by approximately 50%. Inhibition of 5-HT receptor 2A (R 2A) with ketaserin blocked PLD activation by 5-HT. Inhibition with PI3-kinase inhibitor failed to block either activation of PLD by 5-HT or PA-dependent S6K1 phosphorylation. Taken together, these results indicate that ligation of the 5-HTR 2A by 5-HT initiates PLD activation in SMCs, and that its product, PA, is an early signaling molecule in 5-HT-induced pulmonary artery SMC proliferation. Signaling by PA produces its downstream effects primarily through the
mTOR
/S6K1 pathway and to a lesser extent through the ERK pathway. Hydrolysis of cell membrane lipid may be important in vascular effects of 5-HT.
...
PMID:Phospholipase D signaling in serotonin-induced mitogenesis of pulmonary artery smooth muscle cells. 1862 11
The
mammalian target of rapamycin
(
mTOR
) assembles a signaling network that transduces nutrient signals and various other stimuli to regulate a wide range of cellular functions. Of the two distinct
mTOR
complexes, mTORC1 is under the control of the TSC-Rheb pathway, which serves as an integrator of multiple upstream signals. A lipid signaling cascade involving phospholipase D (PLD) and phosphatidic acid (PA) has also been known to mediate mitogenic signals upstream of mTORC1. A new study now reveals a direct connection between these two regulatory pathways and demonstrates that
PLD1
is an effector of Rheb in the activation of mTORC1. A novel role of PLD as a nutrient sensor has also been suggested. In this extra-view, we discuss the emerging importance of PA and PLD in the mTORC1 signaling network and the biological processes it governs. We also consider the implications from several recent findings and propose mechanistic models of PLD-
mTOR
signaling to be tested in the near future.
...
PMID:mTOR signaling: PLD takes center stage. 1892 11
The signalling function of
mTOR
complex 1 is activated by Rheb-GTP, which controls the catalytic competence of the
mTOR
(
mammalian target of rapamycin
) kinase domain by an incompletely understood mechanism. Rheb can bind directly to the
mTOR
kinase domain, and association with inactive nucleotide-deficient Rheb mutants traps
mTOR
in a catalytically inactive state. Nevertheless, Rheb-GTP targets other than
mTOR
, such as FKBP38 (FK506-binding protein 38) and/or
PLD1
(phospholipase D(1)), may also contribute to
mTOR
activation. Once activated, the
mTOR
catalytic domain phosphorylates substrates only when they are bound to raptor (regulatory associated protein of mTOR), a separate polypeptide within the complex. The mechanism of insulin/nutrient stimulation of
mTOR
complex 1 signalling, in addition to Rheb-GTP activation of the
mTOR
catalytic function, also involves a stable modification of the configuration of mTORC1 (
mTOR
complex 1) that increases access of substrates to their binding site on the raptor polypeptide. The mechanism underlying this second step in the activation of mTORC1 is unknown.
...
PMID:Activation of mTORC1 in two steps: Rheb-GTP activation of catalytic function and increased binding of substrates to raptor. 1914 36
Phosphatidic acid (PA) is a pleiotropic lipid second messenger in mammalian cells. We report here that extracellular PA acts as a leukocyte chemoattractant, as membrane-soluble dioleoyl-PA (DOPA) elicits actin polymerization and chemotaxis of human neutrophils and differentiated proleukemic HL-60 cells. We show that the mechanism for this involves the S6 kinase (S6K) signaling enzyme. Chemotaxis was inhibited >90% by the S6K inhibitors rapamycin and bisindolylmaleimide and by S6K1 silencing using double-stranded RNA. However, it was only moderately ( approximately 30%) inhibited by
mTOR
siRNA, indicating the presence of an
mTOR
-independent mechanism for S6K. Exogenous PA led to robust time- and dose-dependent increases in S6K enzymatic activity and Thr(421)/Ser(424) phosphorylation, further supporting a PA/S6K connection. We also investigated whether intracellular PA production affects cell migration. Overexpression of phospholipase D2 (PLD2) and, to a lesser extent,
PLD1
, resulted in elevation of both S6K activity and chemokinesis, whereas PLD silencing was inhibitory. Because the lipase-inactive PLD2 mutants K444R and K758R neither activated S6K nor induced chemotaxis, intracellular PA is needed for this form of cell migration. Lastly, we demonstrated a connection between extracellular and intracellular PA. Using an enhanced green fluorescent protein-derived PA sensor (pEGFP-Spo20PABD), we showed that exogenous PA or PA generated in situ by bacterial (Streptomyces chromofuscus) PLD enters the cell and accumulates in vesicle-like cytoplasmic structures. In summary, we report the discovery of PA as a leukocyte chemoattractant via cell entry and activation of S6K to mediate the cytoskeletal actin polymerization and leukocyte chemotaxis required for the immune function of these cells.
...
PMID:Phosphatidic acid is a leukocyte chemoattractant that acts through S6 kinase signaling. 2030 30
1
2
3
4
Next >>